January 4, 2024 07:12 AM EST
R&D
Cell/Gene Tx

Bay­er and AskBio re­veal ear­ly safe­ty da­ta for Parkin­son's gene ther­a­py, plot PhII study

Katherine Lewin

News Reporter

Bay­er and its sub­sidiary AskBio tout­ed ear­ly da­ta from a small, ear­ly tri­al eval­u­at­ing the safe­ty of its gene ther­a­py for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

What will phar­ma's share buy­back shop­ping spree mean for M&A?

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times